"VSports app下载" Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- PMID: 21368834
- DOI: 10.1038/nature09779
VSports注册入口 - Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
VSports - Erratum in
- Nature. 2011 Jul 7;475(7354):122
Abstract
Microtubules have pivotal roles in fundamental cellular processes and are targets of antitubulin chemotherapeutics. Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various malignancies, including ovarian and breast adenocarcinomas, non-small-cell lung cancer, leukaemias and lymphomas. These agents arrest cells in mitosis and subsequently induce cell death through poorly defined mechanisms. The strategies that resistant tumour cells use to evade death induced by antitubulin agents are also unclear. Here we show that the pro-survival protein MCL1 (ref. 3) is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics. During mitotic arrest, MCL1 protein levels decline markedly, through a post-translational mechanism, potentiating cell death. Phosphorylation of MCL1 directs its interaction with the tumour-suppressor protein FBW7, which is the substrate-binding component of a ubiquitin ligase complex. The polyubiquitylation of MCL1 then targets it for proteasomal degradation VSports手机版. The degradation of MCL1 was blocked in patient-derived tumour cells that lacked FBW7 or had loss-of-function mutations in FBW7, conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy. Additionally, primary tumour samples were enriched for FBW7 inactivation and elevated MCL1 levels, underscoring the prominent roles of these proteins in oncogenesis. Our findings suggest that profiling the FBW7 and MCL1 status of tumours, in terms of protein levels, messenger RNA levels and genetic status, could be useful to predict the response of patients to antitubulin chemotherapeutics. .
Comment in
-
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agents.Pharmacogenomics. 2011 Oct;12(10):1379-80. doi: 10.2217/pgs.11.112. Pharmacogenomics. 2011. PMID: 22008046 No abstract available.
References
-
- Mol Cell. 2005 Feb 4;17(3):393-403 - PubMed (VSports app下载)
-
- Cell. 1995 Apr 21;81(2):279-88 - PubMed
-
- Oncogene. 2008 Jul 24;27(32):4411-21 - PubMed
-
- Science. 2007 Feb 9;315(5813):856-9 - PubMed
-
- Nature. 2006 Apr 13;440(7086):954-8 - PubMed
Publication types
- "V体育2025版" Actions
MeSH terms
- Actions (VSports在线直播)
- Actions (V体育平台登录)
- "VSports" Actions
- "VSports" Actions
- "VSports app下载" Actions
- Actions (V体育ios版)
- Actions (V体育ios版)
- Actions (V体育官网)
- Actions (V体育平台登录)
- VSports手机版 - Actions
- "V体育平台登录" Actions
- Actions (VSports最新版本)
- V体育官网 - Actions
- "VSports在线直播" Actions
- "V体育官网入口" Actions
Substances
- "VSports app下载" Actions
- "V体育官网入口" Actions
- Actions (VSports手机版)
- Actions (VSports手机版)
- V体育安卓版 - Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases (V体育安卓版)
